BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-2064. [PMID: 12086758 DOI: 10.1016/s0140-6736(02)08904-3] [Cited by in Crossref: 341] [Cited by in F6Publishing: 157] [Article Influence: 17.9] [Reference Citation Analysis]
Number Citing Articles
1 Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;CD000171. [PMID: 20091503 DOI: 10.1002/14651858.cd000171.pub3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 180] [Article Influence: 10.8] [Reference Citation Analysis]
2 Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding antiretroviral options in resource-limited settings--a cost-effectiveness analysis. J Acquir Immune Defic Syndr 2009;52:106-13. [PMID: 19448557 DOI: 10.1097/QAI.0b013e3181a4f9c4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pettit AC, Mendes A, Jenkins C, Napravnik S, Freeman A, Shepherd BE, Dowdy D, Gill J, Rachlis A, Moore R, Sterling TR; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) investigators of International epidemiologic Databases to Evaluate AIDS (IeDEA). Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. J Acquir Immune Defic Syndr 2016;72:572-8. [PMID: 27049511 DOI: 10.1097/QAI.0000000000001018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Dowdy DW, Dye C, Cohen T. Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'. Int J Tuberc Lung Dis 2013;17:866-77. [PMID: 23743307 DOI: 10.5588/ijtld.12.0573] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 6.0] [Reference Citation Analysis]
5 DeRiemer K, Kawamura LM, Hopewell PC, Daley CL. Quantitative impact of human immunodeficiency virus infection on tuberculosis dynamics. Am J Respir Crit Care Med 2007;176:936-44. [PMID: 17690336 DOI: 10.1164/rccm.200603-440OC] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
6 Louwagie GM, Bachmann MO, Meyer K, Booysen Fle R, Fairall LR, Heunis C. Highly active antiretroviral treatment and health related quality of life in South African adults with human immunodeficiency virus infection: A cross-sectional analytical study. BMC Public Health 2007;7:244. [PMID: 17854510 DOI: 10.1186/1471-2458-7-244] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
7 Shenoi SV, Brooks RP, Barbour R, Altice FL, Zelterman D, Moll AP, Master I, van der Merwe TL, Friedland GH. Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa. PLoS One 2012;7:e31786. [PMID: 22412840 DOI: 10.1371/journal.pone.0031786] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
8 Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008;168:1910-8. [PMID: 18809819 DOI: 10.1001/archinternmed.2008.1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 5.1] [Reference Citation Analysis]
9 Maier M, Andia I, Emenyonu N, Guzman D, Kaida A, Pepper L, Hogg R, Bangsberg DR. Antiretroviral therapy is associated with increased fertility desire, but not pregnancy or live birth, among HIV+ women in an early HIV treatment program in rural Uganda. AIDS Behav 2009;13 Suppl 1:28-37. [PMID: 18389364 DOI: 10.1007/s10461-008-9371-7] [Cited by in Crossref: 111] [Cited by in F6Publishing: 94] [Article Influence: 8.5] [Reference Citation Analysis]
10 Golub JE, Durovni B, King BS, Cavalacante SC, Pacheco AG, Moulton LH, Moore RD, Chaisson RE, Saraceni V. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2008;22:2527-33. [PMID: 19005276 DOI: 10.1097/QAD.0b013e328311ac4e] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
11 Riou C, Strickland N, Soares AP, Corleis B, Kwon DS, Wherry EJ, Wilkinson RJ, Burgers WA. HIV Skews the Lineage-Defining Transcriptional Profile of Mycobacterium tuberculosis-Specific CD4+ T Cells. J Immunol 2016;196:3006-18. [PMID: 26927799 DOI: 10.4049/jimmunol.1502094] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
12 Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009;38:1612-21. [PMID: 19448046 DOI: 10.1093/ije/dyp208] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
13 Kalsdorf B, Scriba TJ, Wood K, Day CL, Dheda K, Dawson R, Hanekom WA, Lange C, Wilkinson RJ. HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria. Am J Respir Crit Care Med 2009;180:1262-70. [PMID: 19797156 DOI: 10.1164/rccm.200907-1011OC] [Cited by in Crossref: 109] [Cited by in F6Publishing: 63] [Article Influence: 9.1] [Reference Citation Analysis]
14 Girardi E, Palmieri F, Angeletti C, Vanacore P, Matteelli A, Gori A, Carbonara S, Ippolito G. Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis. Clin Dev Immunol 2012;2012:931325. [PMID: 22489253 DOI: 10.1155/2012/931325] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
15 Robertson KR, Oladeji B, Jiang H, Kumwenda J, Supparatpinyo K, Campbell TB, Hakim J, Tripathy S, Hosseinipour MC, Marra CM, Kumarasamy N, Evans S, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhaber C, Price R, Marcus C, Berzins B, Masih R, Lalloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, Hall C; 5199 Study Team; and the AIDS Clinical Trials Group. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clin Infect Dis 2019;68:1739-46. [PMID: 30137250 DOI: 10.1093/cid/ciy718] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
16 Mthiyane T, Pym A, Dheda K, Rustomjee R, Reddy T, Manie S. Longitudinal assessment of health related quality of life of HIV infected patients treated for tuberculosis and HIV in a high burden setting. Qual Life Res 2016;25:3067-76. [PMID: 27277213 DOI: 10.1007/s11136-016-1332-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
17 Damtie D, Yismaw G, Woldeyohannes D, Anagaw B. Common opportunistic infections and their CD4 cell correlates among HIV-infected patients attending at antiretroviral therapy clinic of Gondar University Hospital, Northwest Ethiopia. BMC Res Notes 2013;6:534. [PMID: 24330921 DOI: 10.1186/1756-0500-6-534] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
18 Nahid P, Gonzalez LC, Rudoy I, de Jong BC, Unger A, Kawamura LM, Osmond DH, Hopewell PC, Daley CL. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007;175:1199-206. [PMID: 17290042 DOI: 10.1164/rccm.200509-1529OC] [Cited by in Crossref: 86] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
19 Komati S, Shaw PA, Stubbs N, Mathibedi MJ, Malan L, Sangweni P, Metcalf JA, Masur H, Hassim S. Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS 2010;24:1849-55. [PMID: 20622529 DOI: 10.1097/QAD.0b013e32833a2507] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
20 Skolimowska KH, Rangaka MX, Meintjes G, Pepper DJ, Seldon R, Matthews K, Wilkinson RJ, Wilkinson KA. Altered ratio of IFN-γ/IL-10 in patients with drug resistant Mycobacterium tuberculosis and HIV- Tuberculosis Immune Reconstitution Inflammatory Syndrome. PLoS One 2012;7:e46481. [PMID: 23071578 DOI: 10.1371/journal.pone.0046481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
21 Metcalfe JZ, Porco TC, Westenhouse J, Damesyn M, Facer M, Hill J, Xia Q, Watt JP, Hopewell PC, Flood J. Tuberculosis and HIV co-infection, California, USA, 1993–2008. Emerg Infect Dis 2013;19:400-6. [PMID: 23745218 DOI: 10.3201/eid1903.121521] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
22 Ramachandran G, Hemanth Kumar AK, Rajasekaran S, Kumar P, Ramesh K, Anitha S, Narendran G, Menon P, Gomathi C, Swaminathan S. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India. Antimicrob Agents Chemother 2009;53:863-8. [PMID: 19124658 DOI: 10.1128/AAC.00899-08] [Cited by in Crossref: 46] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
23 Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepelman AI, Manabe YC. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 2010;5:e10527. [PMID: 20479873 DOI: 10.1371/journal.pone.0010527] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 5.0] [Reference Citation Analysis]
24 Mvelase NR, Balakrishna Y, Lutchminarain K, Mlisana K. Evolving rifampicin and isoniazid mono-resistance in a high multidrug-resistant and extensively drug-resistant tuberculosis region: a retrospective data analysis. BMJ Open 2019;9:e031663. [PMID: 31699736 DOI: 10.1136/bmjopen-2019-031663] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Rochon PA, Gurwitz JH, Sykora K, Mamdani M, Streiner DL, Garfinkel S, Normand SL, Anderson GM. Reader's guide to critical appraisal of cohort studies: 1. Role and design. BMJ 2005;330:895-7. [PMID: 15831878 DOI: 10.1136/bmj.330.7496.895] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 6.8] [Reference Citation Analysis]
26 Bacaër N, Ouifki R, Pretorius C, Wood R, Williams B. Modeling the joint epidemics of TB and HIV in a South African township. J Math Biol 2008;57:557-93. [PMID: 18414866 DOI: 10.1007/s00285-008-0177-z] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 5.1] [Reference Citation Analysis]
27 Onyango DO, Yuen CM, Cain KP, Ngari F, Masini EO, Borgdorff MW. Reduction of HIV-associated excess mortality by antiretroviral treatment among tuberculosis patients in Kenya. PLoS One 2017;12:e0188235. [PMID: 29145454 DOI: 10.1371/journal.pone.0188235] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
28 Maheswaran H, Barton P. Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis. PLoS One 2012;7:e30457. [PMID: 22291958 DOI: 10.1371/journal.pone.0030457] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
29 Marks SM, Magee E, Robison V. Patients diagnosed with tuberculosis at death or who died during therapy: association with the human immunodeficiency virus. Int J Tuberc Lung Dis 2011;15:465-70. [PMID: 21396204 DOI: 10.5588/ijtld.10.0259] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
30 Meijerink H, Wisaksana R, Lestari M, Meilana I, Chaidir L, van der Ven AJ, Alisjahbana B, van Crevel R. Active and latent tuberculosis among HIV-positive injecting drug users in Indonesia. J Int AIDS Soc 2015;18:19317. [PMID: 25690530 DOI: 10.7448/IAS.18.1.19317] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
31 Saito S, Mpofu P, Carter EJ, Diero L, Wools-Kaloustian KK, Yiannoutsos CT, Beverly MS, Tsiouris S, Somi GR, Ssali J, Nash D, Elul B. Implementation and Operational Research: Declining Tuberculosis Incidence Among People Receiving HIV Care and Treatment Services in East Africa, 2007-2012. J Acquir Immune Defic Syndr 2016;71:e96-e106. [PMID: 26910387 DOI: 10.1097/QAI.0000000000000896] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Iroezindu MO. Disparities in the Magnitude of Human Immunodeficiency Virus-related Opportunistic Infections Between High and Low/Middle-income Countries: Is Highly Active Antiretroviral Therapy Changing the Trend? Ann Med Health Sci Res 2016;6:4-18. [PMID: 27144071 DOI: 10.4103/2141-9248.180234] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
33 Tiruneh F, Deyas Y. Effect of highly active antiretroviral treatment on TB incidence among HIV infected children and their clinical profile, retrospective cohort study, South West Ethiopia. Sci Rep 2020;10:21468. [PMID: 33293656 DOI: 10.1038/s41598-020-78466-0] [Reference Citation Analysis]
34 Breen RA, Swaden L, Ballinger J, Lipman MC. Tuberculosis and HIV co-infection: a practical therapeutic approach. Drugs 2006;66:2299-308. [PMID: 17181373 DOI: 10.2165/00003495-200666180-00003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
35 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
36 Tadokera R, Meintjes G, Skolimowska KH, Wilkinson KA, Matthews K, Seldon R, Chegou NN, Maartens G, Rangaka MX, Rebe K, Walzl G, Wilkinson RJ. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Respir J 2011;37:1248-59. [PMID: 20817712 DOI: 10.1183/09031936.00091010] [Cited by in Crossref: 101] [Cited by in F6Publishing: 102] [Article Influence: 9.2] [Reference Citation Analysis]
37 Hwang JH, Choe PG, Kim NH, Bang JH, Song KH, Park WB, Kim ES, Park SW, Kim HB, Kim NJ, Oh MD, Choe KW. Incidence and risk factors of tuberculosis in patients with human immunodeficiency virus infection. J Korean Med Sci 2013;28:374-7. [PMID: 23486534 DOI: 10.3346/jkms.2013.28.3.374] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
38 Walensky RP, Wood R, Weinstein MC, Martinson NA, Losina E, Fofana MO, Goldie SJ, Divi N, Yazdanpanah Y, Wang B, Paltiel AD, Freedberg KA; CEPAC-International Investigators. Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis 2008;197:1324-32. [PMID: 18422445 DOI: 10.1086/587184] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
39 Deuffic-Burban S, Losina E, Wang B, Gabillard D, Messou E, Divi N, Freedberg KA, Anglaret X, Yazdanpanah Y. Estimates of opportunistic infection incidence or death within specific CD4 strata in HIV-infected patients in Abidjan, Côte d'Ivoire: impact of alternative methods of CD4 count modelling. Eur J Epidemiol 2007;22:737-44. [PMID: 17828437 DOI: 10.1007/s10654-007-9175-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
40 Morris A, Crothers K, Beck JM, Huang L; American Thoracic Society Committee on HIV Pulmonary Disease. An official ATS workshop report: Emerging issues and current controversies in HIV-associated pulmonary diseases. Proc Am Thorac Soc 2011;8:17-26. [PMID: 21364216 DOI: 10.1513/pats.2009-047WS] [Cited by in Crossref: 35] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
41 Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, Dansereau EA, Graetz N, Barber RM, Brown JC, Wang H, Duber HC, Naghavi M, Dicker D, Dandona L, Salomon JA, Heuton KR, Foreman K, Phillips DE, Fleming TD, Flaxman AD, Phillips BK, Johnson EK, Coggeshall MS, Abd-Allah F, Abera SF, Abraham JP, Abubakar I, Abu-Raddad LJ, Abu-Rmeileh NM, Achoki T, Adeyemo AO, Adou AK, Adsuar JC, Agardh EE, Akena D, Al Kahbouri MJ, Alasfoor D, Albittar MI, Alcalá-Cerra G, Alegretti MA, Alemu ZA, Alfonso-Cristancho R, Alhabib S, Ali R, Alla F, Allen PJ, Alsharif U, Alvarez E, Alvis-Guzman N, Amankwaa AA, Amare AT, Amini H, Ammar W, Anderson BO, Antonio CA, Anwari P, Arnlöv J, Arsenijevic VS, Artaman A, Asghar RJ, Assadi R, Atkins LS, Badawi A, Balakrishnan K, Banerjee A, Basu S, Beardsley J, Bekele T, Bell ML, Bernabe E, Beyene TJ, Bhala N, Bhalla A, Bhutta ZA, Abdulhak AB, Binagwaho A, Blore JD, Basara BB, Bose D, Brainin M, Breitborde N, Castañeda-Orjuela CA, Catalá-López F, Chadha VK, Chang JC, Chiang PP, Chuang TW, Colomar M, Cooper LT, Cooper C, Courville KJ, Cowie BC, Criqui MH, Dandona R, Dayama A, De Leo D, Degenhardt L, Del Pozo-Cruz B, Deribe K, Des Jarlais DC, Dessalegn M, Dharmaratne SD, Dilmen U, Ding EL, Driscoll TR, Durrani AM, Ellenbogen RG, Ermakov SP, Esteghamati A, Faraon EJ, Farzadfar F, Fereshtehnejad SM, Fijabi DO, Forouzanfar MH, Fra Paleo U, Gaffikin L, Gamkrelidze A, Gankpé FG, Geleijnse JM, Gessner BD, Gibney KB, Ginawi IA, Glaser EL, Gona P, Goto A, Gouda HN, Gugnani HC, Gupta R, Gupta R, Hafezi-Nejad N, Hamadeh RR, Hammami M, Hankey GJ, Harb HL, Haro JM, Havmoeller R, Hay SI, Hedayati MT, Pi IB, Hoek HW, Hornberger JC, Hosgood HD, Hotez PJ, Hoy DG, Huang JJ, Iburg KM, Idrisov BT, Innos K, Jacobsen KH, Jeemon P, Jensen PN, Jha V, Jiang G, Jonas JB, Juel K, Kan H, Kankindi I, Karam NE, Karch A, Karema CK, Kaul A, Kawakami N, Kazi DS, Kemp AH, Kengne AP, Keren A, Kereselidze M, Khader YS, Khalifa SE, Khan EA, Khang YH, Khonelidze I, Kinfu Y, Kinge JM, Knibbs L, Kokubo Y, Kosen S, Defo BK, Kulkarni VS, Kulkarni C, Kumar K, Kumar RB, Kumar GA, Kwan GF, Lai T, Balaji AL, Lam H, Lan Q, Lansingh VC, Larson HJ, Larsson A, Lee JT, Leigh J, Leinsalu M, Leung R, Li Y, Li Y, De Lima GM, Lin HH, Lipshultz SE, Liu S, Liu Y, Lloyd BK, Lotufo PA, Machado VM, Maclachlan JH, Magis-Rodriguez C, Majdan M, Mapoma CC, Marcenes W, Marzan MB, Masci JR, Mashal MT, Mason-Jones AJ, Mayosi BM, Mazorodze TT, Mckay AC, Meaney PA, Mehndiratta MM, Mejia-Rodriguez F, Melaku YA, Memish ZA, Mendoza W, Miller TR, Mills EJ, Mohammad KA, Mokdad AH, Mola GL, Monasta L, Montico M, Moore AR, Mori R, Moturi WN, Mukaigawara M, Murthy KS, Naheed A, Naidoo KS, Naldi L, Nangia V, Narayan KM, Nash D, Nejjari C, Nelson RG, Neupane SP, Newton CR, Ng M, Nisar MI, Nolte S, Norheim OF, Nowaseb V, Nyakarahuka L, Oh IH, Ohkubo T, Olusanya BO, Omer SB, Opio JN, Orisakwe OE, Pandian JD, Papachristou C, Caicedo AJ, Patten SB, Paul VK, Pavlin BI, Pearce N, Pereira DM, Pervaiz A, Pesudovs K, Petzold M, Pourmalek F, Qato D, Quezada AD, Quistberg DA, Rafay A, Rahimi K, Rahimi-Movaghar V, Ur Rahman S, Raju M, Rana SM, Razavi H, Reilly RQ, Remuzzi G, Richardus JH, Ronfani L, Roy N, Sabin N, Saeedi MY, Sahraian MA, Samonte GM, Sawhney M, Schneider IJ, Schwebel DC, Seedat S, Sepanlou SG, Servan-Mori EE, Sheikhbahaei S, Shibuya K, Shin HH, Shiue I, Shivakoti R, Sigfusdottir ID, Silberberg DH, Silva AP, Simard EP, Singh JA, Skirbekk V, Sliwa K, Soneji S, Soshnikov SS, Sreeramareddy CT, Stathopoulou VK, Stroumpoulis K, Swaminathan S, Sykes BL, Tabb KM, Talongwa RT, Tenkorang EY, Terkawi AS, Thomson AJ, Thorne-Lyman AL, Towbin JA, Traebert J, Tran BX, Dimbuene ZT, Tsilimbaris M, Uchendu US, Ukwaja KN, Uzun SB, Vallely AJ, Vasankari TJ, Venketasubramanian N, Violante FS, Vlassov VV, Vollset SE, Waller S, Wallin MT, Wang L, Wang X, Wang Y, Weichenthal S, Weiderpass E, Weintraub RG, Westerman R, White RA, Wilkinson JD, Williams TN, Woldeyohannes SM, Wong JQ, Xu G, Yang YC, Yano Y, Yentur GK, Yip P, Yonemoto N, Yoon SJ, Younis M, Yu C, Jin KY, El Sayed Zaki M, Zhao Y, Zheng Y, Zhou M, Zhu J, Zou XN, Lopez AD, Vos T. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:1005-70. [PMID: 25059949 DOI: 10.1016/S0140-6736(14)60844-8] [Cited by in Crossref: 582] [Cited by in F6Publishing: 365] [Article Influence: 83.1] [Reference Citation Analysis]
42 Tilahun M, Shibabaw A, Kiflie A, Bewket G, Abate E, Gelaw B. Latent tuberculosis infection and associated risk factors among people living with HIV and apparently healthy blood donors at the University of Gondar referral hospital, Northwest Ethiopia. BMC Res Notes 2019;12:515. [PMID: 31420007 DOI: 10.1186/s13104-019-4548-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Harling G, Orrell C, Wood R. Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res 2007;7:80. [PMID: 17555564 DOI: 10.1186/1472-6963-7-80] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kasaie P, Mathema B, Kelton WD, Azman AS, Pennington J, Dowdy DW. A Novel Tool Improves Existing Estimates of Recent Tuberculosis Transmission in Settings of Sparse Data Collection. PLoS One 2015;10:e0144137. [PMID: 26679499 DOI: 10.1371/journal.pone.0144137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
45 Han SH, Zhou J, Lee MP, Zhao H, Chen YM, Kumarasamy N, Pujari S, Lee C, Omar SF, Ditangco R, Phanuphak N, Kiertiburanakul S, Chaiwarith R, Merati TP, Yunihastuti E, Tanuma J, Saphonn V, Sohn AH, Choi JY; TREAT Asia HIV Observational Database. Prognostic significance of the interval between the initiation of antiretroviral therapy and the initiation of anti-tuberculosis treatment in HIV/tuberculosis-coinfected patients: results from the TREAT Asia HIV Observational Database. HIV Med 2014;15:77-85. [PMID: 23980589 DOI: 10.1111/hiv.12073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
46 Batista Jd, de Albuquerque Mde F, Maruza M, Ximenes RA, Santos ML, Montarroyos UR, de Barros Miranda-Filho D, Lacerda HR, Rodrigues LC. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One 2013;8:e63916. [PMID: 23675515 DOI: 10.1371/journal.pone.0063916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
47 Zachariah R, Van Damme W, Arendt V, Schmit JC, Harries AD. The HIV/AIDS epidemic in sub-Saharan Africa: thinking ahead on programmatic tasks and related operational research. J Int AIDS Soc 2011;14 Suppl 1:S7. [PMID: 21967983 DOI: 10.1186/1758-2652-14-S1-S7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
48 Cheng MP, Hirji A, Roth DZ, Cook VJ, Lima VD, Montaner JS, Johnston JC. Tuberculosis in HIV-infected persons in British Columbia during the HAART era. Can J Public Health 2014;105:e258-62. [PMID: 25166127 DOI: 10.17269/cjph.105.4260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
49 Venkatesh KK, Lurie MN, Mayer KH. How HIV treatment could result in effective prevention. Future Virol 2010;5:405-15. [PMID: 20814447 DOI: 10.2217/fvl.10.38] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
50 Alvarez-Uria G, Pakam R, Midde M, Naik PK. Incidence and mortality of tuberculosis before and after initiation of antiretroviral therapy: an HIV cohort study in India. J Int AIDS Soc 2014;17:19251. [PMID: 25499123 DOI: 10.7448/IAS.17.1.19251] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
51 Varma JK, Wiriyakitjar D, Nateniyom S, Anuwatnonthakate A, Monkongdee P, Sumnapan S, Akksilp S, Sattayawuthipong W, Charunsuntonsri P, Rienthong S, Yamada N, Akarasewi P, Wells CD, Tappero JW. Evaluating the potential impact of the new Global Plan to Stop TB: Thailand, 2004-2005. Bull World Health Organ 2007;85:586-92. [PMID: 17768516 DOI: 10.2471/blt.06.038067] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
52 Geremew D, Endalamaw A, Negash M, Eshetie S, Tessema B. The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. BMC Infect Dis 2019;19:405. [PMID: 31077133 DOI: 10.1186/s12879-019-4031-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
53 Sah SK, Sahu SK, Lamichhane B, Bhatta GK, Bhandari KB, Owiti P, Majumdar SS. Dotting the Three I's for collaborative TB-HIV activities: evaluation of a pilot programme in Kathmandu, Nepal. Public Health Action 2016;6:169-75. [PMID: 27695679 DOI: 10.5588/pha.16.0012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
54 Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009;30:685-99, viii. [PMID: 19925961 DOI: 10.1016/j.ccm.2009.08.010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
55 Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8:e1000391. [PMID: 21267059 DOI: 10.1371/journal.pmed.1000391] [Cited by in Crossref: 223] [Cited by in F6Publishing: 230] [Article Influence: 22.3] [Reference Citation Analysis]
56 Pho MT, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler LM, Scott CA, Mayer KH, Freedberg KA, Walensky RP. The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. PLoS One. 2012;7:e36001. [PMID: 22558301 DOI: 10.1371/journal.pone.0036001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
57 Hanrahan CF, Golub JE, Mohapi L, Tshabangu N, Modisenyane T, Chaisson RE, Gray GE, McIntyre JA, Martinson NA. Body mass index and risk of tuberculosis and death. AIDS 2010;24:1501-8. [PMID: 20505496 DOI: 10.1097/QAD.0b013e32833a2a4a] [Cited by in Crossref: 76] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
58 Geremew D, Melku M, Endalamaw A, Woldu B, Fasil A, Negash M, Baynes HW, Geremew H, Teklu T, Deressa T, Tessema B, Sack U. Tuberculosis and its association with CD4+ T cell count among adult HIV positive patients in Ethiopian settings: a systematic review and meta-analysis. BMC Infect Dis 2020;20:325. [PMID: 32380957 DOI: 10.1186/s12879-020-05040-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
59 Tiruneh F, Deyas Y. How Far Does Highly Active Antiretroviral Treatment Reduce TB Incidence among Children? A Marginal Structural Modeling Analysis, Southwest Ethiopia. Ethiop J Health Sci 2020;30:653-60. [PMID: 33911825 DOI: 10.4314/ejhs.v30i5.3] [Reference Citation Analysis]
60 Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270. [PMID: 22911011 DOI: 10.1371/journal.pmed.1001270] [Cited by in Crossref: 221] [Cited by in F6Publishing: 198] [Article Influence: 24.6] [Reference Citation Analysis]
61 Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D. Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001. PLoS One 2007;2:e826. [PMID: 17786198 DOI: 10.1371/journal.pone.0000826] [Cited by in Crossref: 47] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
62 Danyuttapolchai J, Kittimunkong S, Nateniyom S, Painujit S, Klinbuayaem V, Maipanich N, Maokamnerd Y, Pevzner E, Whitehead S, Kanphukiew A, Monkongdee P, Martin M. Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. PLoS One 2017;12:e0184986. [PMID: 28949995 DOI: 10.1371/journal.pone.0184986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
63 Coelho L, Cardoso SW, Amancio RT, Moreira RI, Campos DP, Veloso VG, Grinsztejn B, Luz PM. Trends in AIDS-defining opportunistic illnesses incidence over 25 years in Rio de Janeiro, Brazil. PLoS One 2014;9:e98666. [PMID: 24901419 DOI: 10.1371/journal.pone.0098666] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
64 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
65 Bunjun R, Riou C, Soares AP, Thawer N, Müller TL, Kiravu A, Ginbot Z, Oni T, Goliath R, Kalsdorf B, von Groote-Bidlingmaier F, Hanekom W, Walzl G, Wilkinson RJ, Burgers WA. Effect of HIV on the Frequency and Number of Mycobacterium tuberculosis-Specific CD4+ T Cells in Blood and Airways During Latent M. tuberculosis Infection. J Infect Dis 2017;216:1550-60. [PMID: 29029171 DOI: 10.1093/infdis/jix529] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
66 Bell LC, Pollara G, Pascoe M, Tomlinson GS, Lehloenya RJ, Roe J, Meldau R, Miller RF, Ramsay A, Chain BM, Dheda K, Noursadeghi M. In Vivo Molecular Dissection of the Effects of HIV-1 in Active Tuberculosis. PLoS Pathog 2016;12:e1005469. [PMID: 26986567 DOI: 10.1371/journal.ppat.1005469] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
67 Wilkinson KA, Seldon R, Meintjes G, Rangaka MX, Hanekom WA, Maartens G, Wilkinson RJ. Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009;180:674-83. [PMID: 19628776 DOI: 10.1164/rccm.200904-0568OC] [Cited by in Crossref: 49] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
68 Samandari T, Bishai D, Luteijn M, Mosimaneotsile B, Motsamai O, Postma M, Hubben G. Costs and consequences of additional chest x-ray in a tuberculosis prevention program in Botswana. Am J Respir Crit Care Med. 2011;183:1103-1111. [PMID: 21148723 DOI: 10.1164/rccm.201004-0620oc] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
69 Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010;16:262-70. [PMID: 20375787 DOI: 10.1097/MCP.0b013e328337f23a] [Cited by in Crossref: 75] [Cited by in F6Publishing: 44] [Article Influence: 6.8] [Reference Citation Analysis]
70 van der Bijl P, Herbst P, Doubell AF. Redefining Effusive-Constrictive Pericarditis with Echocardiography. J Cardiovasc Ultrasound 2016;24:317-23. [PMID: 28090260 DOI: 10.4250/jcu.2016.24.4.317] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
71 Gunda DW, Maganga SC, Nkandala I, Kilonzo SB, Mpondo BC, Shao ER, Kalluvya SE. Prevalence and Risk Factors of Active TB among Adult HIV Patients Receiving ART in Northwestern Tanzania: A Retrospective Cohort Study. Can J Infect Dis Med Microbiol 2018;2018:1346104. [PMID: 30073038 DOI: 10.1155/2018/1346104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
72 Masuka JT, Chipangura P, Nyambayo PP, Stergachis A, Khoza S. A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe. Clin Drug Investig 2018;38:9-17. [PMID: 28965312 DOI: 10.1007/s40261-017-0579-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
73 Wood R, Lawn SD. Antiretroviral treatment as prevention: impact of the 'test and treat' strategy on the tuberculosis epidemic. Curr HIV Res 2011;9:383-92. [PMID: 21999773 DOI: 10.2174/157016211798038524] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
74 Surie D, Borgdorff MW, Cain KP, Click ES, DeCock KM, Yuen CM. Assessing the impact of antiretroviral therapy on tuberculosis notification rates among people with HIV: a descriptive analysis of 23 countries in sub-Saharan Africa, 2010-2015. BMC Infect Dis 2018;18:481. [PMID: 30257667 DOI: 10.1186/s12879-018-3387-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
75 Yan I, Bendavid E, Korenromp EL. Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis. PLoS One 2016;11:e0160481. [PMID: 27536864 DOI: 10.1371/journal.pone.0160481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
76 Wolday D, Kebede Y, Legesse D, Siraj DS, McBride JA, Kirsch MJ, Striker R. Role of CD4/CD8 ratio on the incidence of tuberculosis in HIV-infected patients on antiretroviral therapy followed up for more than a decade. PLoS One 2020;15:e0233049. [PMID: 32442166 DOI: 10.1371/journal.pone.0233049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
77 Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick RM, Johnson WD Jr, Pape JW, Fitzgerald DW. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363:257-65. [PMID: 20647201 DOI: 10.1056/NEJMoa0910370] [Cited by in Crossref: 256] [Cited by in F6Publishing: 150] [Article Influence: 23.3] [Reference Citation Analysis]
78 Zhou J, Elliott J, Li PC, Lim PL, Kiertiburanakul S, Kumarasamy N, Merati TP, Pujari S, Chen YM, Phanuphak P, Vonthanak S, Sirisanthana T, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang F, Tau G, Ditangco R. Risk and prognostic significance of tuberculosis in patients from The TREAT Asia HIV Observational Database. BMC Infect Dis 2009;9:46. [PMID: 19383122 DOI: 10.1186/1471-2334-9-46] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
79 Albalak R, O'Brien RJ, Kammerer JS, O'Brien SM, Marks SM, Castro KG, Moore M. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. Arch Intern Med 2007;167:2443-52. [PMID: 18071166 DOI: 10.1001/archinte.167.22.2443] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
80 Awadalla H, El-Samani F, Soghaier MA, Makki M. Risk Factors Associated with the Development of Tuberculosis Among HIV-Infected Patients in Khartoum in 2010. AIMS Public Health 2015;2:784-92. [PMID: 29546135 DOI: 10.3934/publichealth.2015.4.784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
81 Houlihan CF, Mutevedzi PC, Lessells RJ, Cooke GS, Tanser FC, Newell ML. The tuberculosis challenge in a rural South African HIV programme. BMC Infect Dis 2010;10:23. [PMID: 20146818 DOI: 10.1186/1471-2334-10-23] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.9] [Reference Citation Analysis]
82 Du Bruyn E, Ruzive S, Lindestam Arlehamn CS, Sette A, Sher A, Barber DL, Wilkinson RJ, Riou C. Mycobacterium tuberculosis-specific CD4 T cells expressing CD153 inversely associate with bacterial load and disease severity in human tuberculosis. Mucosal Immunol 2021;14:491-9. [PMID: 32678272 DOI: 10.1038/s41385-020-0322-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
83 Liebenberg J, van der Bijl P. A "Vanishing", Tuberculous, Pericardial Effusion. Korean Circ J 2016;46:879-81. [PMID: 27826351 DOI: 10.4070/kcj.2016.46.6.879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
84 Pati S, Bhattacharya S, Swain S. Prevalence and Patterns of Multimorbidity among Human Immunodeficiency Virus Positive People in Odisha, India: An Exploratory Study. J Clin Diagn Res 2017;11:LC10-3. [PMID: 28764205 DOI: 10.7860/JCDR/2017/22766.10014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
85 Kufa T, Chihota V, Mngomezulu V, Charalambous S, Verver S, Churchyard G, Borgdorff M. The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. BMC Infect Dis 2016;16:266. [PMID: 27286814 DOI: 10.1186/s12879-016-1598-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
86 Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, Platt RW, Wood R, Beck EJ. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2006;3:e4. [PMID: 16318413 DOI: 10.1371/journal.pmed.0030004] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 4.8] [Reference Citation Analysis]
87 Meintjes G, Wilkinson KA, Rangaka MX, Skolimowska K, van Veen K, Abrahams M, Seldon R, Pepper DJ, Rebe K, Mouton P, van Cutsem G, Nicol MP, Maartens G, Wilkinson RJ. Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008;178:1083-9. [PMID: 18755923 DOI: 10.1164/rccm.200806-858OC] [Cited by in Crossref: 107] [Cited by in F6Publishing: 70] [Article Influence: 8.2] [Reference Citation Analysis]
88 Anandaiah A, Dheda K, Keane J, Koziel H, Moore DA, Patel NR. Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med 2011;183:987-97. [PMID: 21177884 DOI: 10.1164/rccm.201008-1246CI] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
89 Okwera A, Bwanga F, Najjingo I, Mulumba Y, Mafigiri DK, Whalen CC, Joloba ML. Aetiology of pulmonary symptoms in HIV-infected smear negative recurrent PTB suspects in Kampala, Uganda: a cross-sectional study. PLoS One 2013;8:e82257. [PMID: 24312650 DOI: 10.1371/journal.pone.0082257] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
90 Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
91 Akanbi MO, Achenbach CJ, Feinglass J, Taiwo B, Onu A, Pho MT, Agbaji O, Kanki P, Murphy RL. Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort study. AIDS Res Hum Retroviruses 2013;29:931-7. [PMID: 23316724 DOI: 10.1089/AID.2012.0231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
92 Soorju V, Naidoo P. Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal. Afr J Prim Health Care Fam Med 2016;8:e1-6. [PMID: 28155312 DOI: 10.4102/phcfm.v8i1.1171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
93 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
94 Issarow CM, Mulder N, Wood R. Environmental and social factors impacting on epidemic and endemic tuberculosis: a modelling analysis. R Soc Open Sci 2018;5:170726. [PMID: 29410796 DOI: 10.1098/rsos.170726] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
95 Nosyk B, Montaner JS. The evolving landscape of the economics of HIV treatment and prevention. PLoS Med 2012;9:e1001174. [PMID: 22347816 DOI: 10.1371/journal.pmed.1001174] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
96 Fenner L, Atkinson A, Boulle A, Fox MP, Prozesky H, Zürcher K, Ballif M, Furrer H, Zwahlen M, Davies MA, Egger M; International Epidemiology Database to Evaluate AIDS in Southern Africa (IeDEA-SA). HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. J Int AIDS Soc 2017;20:21327. [PMID: 28691438 DOI: 10.7448/IAS.20.1.21327] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
97 Delva W, Eaton JW, Meng F, Fraser C, White RG, Vickerman P, Boily MC, Hallett TB. HIV treatment as prevention: optimising the impact of expanded HIV treatment programmes. PLoS Med 2012;9:e1001258. [PMID: 22802738 DOI: 10.1371/journal.pmed.1001258] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
98 Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG; Asia Pacific HIV Observational Database (APHOD). Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr 2009;50:513-20. [PMID: 19408354 DOI: 10.1097/qai.0b013e31819906d3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
99 Westreich D, MacPhail P, Van Rie A, Malope-Kgokong B, Ive P, Rubel D, Boulmé R, Eron J, Sanne I. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009;23:707-15. [PMID: 19279444 DOI: 10.1097/QAD.0b013e328325d115] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
100 Golub JE, Astemborski J, Ahmed M, Cronin W, Mehta SH, Kirk GD, Vlahov D, Chaisson RE. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr 2008;49:532-7. [PMID: 18989223 DOI: 10.1097/QAI.0b013e31818d5c1c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
101 Charles M, Pape JW. Tuberculosis and HIV: Implications in the developing world. Curr HIV/AIDS Rep 2006;3:139-44. [PMID: 16970841 DOI: 10.1007/BF02696658] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
102 Ogunsola OO, Ajayi O, Ojo O, Adeyeye O, Akinro Y, Oke O, Adurogbola AA, Olajide O. Improving coverage and completion rate of isoniazid preventive therapy among eligible HIV patients using quality improvement approaches: a case study of State Hospital, Ijebu Ode, Ogun State, Nigeria. Pan Afr Med J 2019;34:193. [PMID: 32180867 DOI: 10.11604/pamj.2019.34.193.19360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 De Beaudrap P, Etard JF, Diouf A, Ndiaye I, Ndèye GF, Sow PS, Ndèye KC, Ecochard R, Delaporte E; ANRS 1215 Study Group. Incidence and determinants of new AIDS-defining illnesses after HAART initiation in a Senegalese cohort. BMC Infect Dis 2010;10:179. [PMID: 20565900 DOI: 10.1186/1471-2334-10-179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
104 Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, Chaisson RE, Golub JE. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One 2008;3:e3132. [PMID: 18781195 DOI: 10.1371/journal.pone.0003132] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
105 Zulu I, Schuman P, Musonda R, Chomba E, Mwinga K, Sinkala M, Chisembele M, Mwaba P, Kasonde D, Vermund SH. Priorities for antiretroviral therapy research in sub-Saharan Africa: a 2002 consensus conference in Zambia. J Acquir Immune Defic Syndr 2004;36:831-4. [PMID: 15213567 DOI: 10.1097/00126334-200407010-00010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
106 Orrell C, Cohen K, Conradie F, Zeinecker J, Ive P, Sanne I, Wood R. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther 2011;16:527-34. [PMID: 21685540 DOI: 10.3851/IMP1780] [Cited by in Crossref: 20] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
107 Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012;26:2121-33. [PMID: 22695302 DOI: 10.1097/QAD.0b013e3283565dd1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
108 Solomon FB, Angore BN, Koyra HC, Tufa EG, Berheto TM, Admasu M. Spectrum of opportunistic infections and associated factors among people living with HIV/AIDS in the era of highly active anti-retroviral treatment in Dawro Zone hospital: a retrospective study. BMC Res Notes 2018;11:604. [PMID: 30126450 DOI: 10.1186/s13104-018-3707-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
109 Sinha S, Shekhar RC, Singh G, Shah N, Ahmad H, Kumar N, Sharma SK, Samantaray JC, Ranjan S, Ekka M, Sreenivas V, Mitsuyasu RT. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis 2012;12:168. [PMID: 22846195 DOI: 10.1186/1471-2334-12-168] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
110 Middelkoop K, Bekker LG, Myer L, Whitelaw A, Grant A, Kaplan G, McIntyre J, Wood R. Antiretroviral program associated with reduction in untreated prevalent tuberculosis in a South African township. Am J Respir Crit Care Med 2010;182:1080-5. [PMID: 20558626 DOI: 10.1164/rccm.201004-0598OC] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
111 Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, Efron A, Moore RD, Chaisson RE, Durovni B. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21:1441-1448. [PMID: 17589190 DOI: 10.1097/qad.0b013e328216f441] [Cited by in Crossref: 189] [Cited by in F6Publishing: 119] [Article Influence: 13.5] [Reference Citation Analysis]
112 Etard JF, Diouf A, De Beaudrap P, Akoi K, Ngom-Guèye NF, Ndiaye I, Ecochard R, Sow PS, Eric D. Short and Long-Term Incidence of Tuberculosis and CD4-Cell Count Dynamic on HAART in Senegal. Open AIDS J 2009;3:63-70. [PMID: 20148061 DOI: 10.2174/1874613600903010063] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
113 Mitiku H, Weldegebreal F, Teklemariam Z. Magnitude of opportunistic infections and associated factors in HIV-infected adults on antiretroviral therapy in eastern Ethiopia. HIV AIDS (Auckl) 2015;7:137-44. [PMID: 25999763 DOI: 10.2147/HIV.S79545] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
114 Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr 2011;56:349-55. [PMID: 20926954 DOI: 10.1097/QAI.0b013e3181f9fb39] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
115 Backx M, Curtis H, Freedman A, Johnson M; British HIV Association., BHIVA Clinical Audit Sub-Committee. British HIV Association national audit on the management of patients co-infected with tuberculosis and HIV. Clin Med (Lond) 2011;11:222-6. [PMID: 21902071 DOI: 10.7861/clinmedicine.11-3-222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
116 Lagrange PH, Herrmann JL. Diagnosing latent tuberculosis infection in the HIV era. Open Respir Med J 2008;2:52-9. [PMID: 19343092 DOI: 10.2174/1874306400802010052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
117 Sule WF, Sani ES. CD4(+) T Cell Response to Lamivudine, Stavudine and Nevirapine in Human Immunodeficiency Virus Infected Antiretroviral-Naive Men in Nigeria. Indian J Virol 2011;22:90-7. [PMID: 23637509 DOI: 10.1007/s13337-011-0045-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
118 Wallis RS, Hafner R. Advancing host-directed therapy for tuberculosis. Nat Rev Immunol 2015;15:255-63. [PMID: 25765201 DOI: 10.1038/nri3813] [Cited by in Crossref: 185] [Cited by in F6Publishing: 155] [Article Influence: 30.8] [Reference Citation Analysis]
119 del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012;54:1364-72. [PMID: 22460971 DOI: 10.1093/cid/cis203] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
120 Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A, Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker LG. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007;175:87-93. [PMID: 16973982 DOI: 10.1164/rccm.200606-759OC] [Cited by in Crossref: 151] [Cited by in F6Publishing: 111] [Article Influence: 10.1] [Reference Citation Analysis]
121 Mansoer J, Scheele S, Floyd K, Dye C, Sitienei J, Williams B. New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya. Bull World Health Organ 2009;87:186-92, 192A-B. [PMID: 19377714 DOI: 10.2471/blt.08.051474] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
122 Kufa T, Mabuto T, Muchiri E, Charalambous S, Rosillon D, Churchyard G, Harris RC. Incidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysis. PLoS One 2014;9:e111209. [PMID: 25393281 DOI: 10.1371/journal.pone.0111209] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
123 Gilbert JA, Shenoi SV, Moll AP, Friedland GH, Paltiel AD, Galvani AP. Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One 2016;11:e0165614. [PMID: 27906986 DOI: 10.1371/journal.pone.0165614] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
124 Nayyar E, Torres JA, Malvestutto CD. Tuberculous Gastric Abscess in a Patient with AIDS: A Rare Presentation. Case Rep Infect Dis 2016;2016:5675036. [PMID: 27239353 DOI: 10.1155/2016/5675036] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
125 Deeks SG. Antiretroviral treatment of HIV infected adults. BMJ. 2006;332:1489. [PMID: 16793811 DOI: 10.1136/bmj.332.7556.1489] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
126 Walters E, Cotton MF, Rabie H, Schaaf HS, Walters LO, Marais BJ. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on anti-retroviral therapy. BMC Pediatr 2008;8:1. [PMID: 18186944 DOI: 10.1186/1471-2431-8-1] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 6.6] [Reference Citation Analysis]
127 Chamie G, Luetkemeyer A, Charlebois E, Havlir DV. Tuberculosis as part of the natural history of HIV infection in developing countries. Clin Infect Dis 2010;50 Suppl 3:S245-54. [PMID: 20397955 DOI: 10.1086/651498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
128 Ricks S, Denkinger CM, Schumacher SG, Hallett TB, Arinaminpathy N. The potential impact of urine-LAM diagnostics on tuberculosis incidence and mortality: A modelling analysis. PLoS Med 2020;17:e1003466. [PMID: 33306694 DOI: 10.1371/journal.pmed.1003466] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
129 Fenner L, Forster M, Boulle A, Phiri S, Braitstein P, Lewden C, Schechter M, Kumarasamy N, Pascoe M, Sprinz E, Bangsberg DR, Sow PS, Dickinson D, Fox MP, McIntyre J, Khongphatthanayothin M, Dabis F, Brinkhof MW, Wood R, Egger M; ART-LINC of IeDEA. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis 2011;15:620-7. [PMID: 21756512 DOI: 10.5588/ijtld.10.0249] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
130 Middelkoop K, Bekker LG, Myer L, Johnson LF, Kloos M, Morrow C, Wood R. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr 2011;56:263-9. [PMID: 21317585 DOI: 10.1097/QAI.0b013e31820413b3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
131 Sanchez-Padilla E, Dlamini T, Ascorra A, Rüsch-Gerdes S, Tefera ZD, Calain P, de la Tour R, Jochims F, Richter E, Bonnet M. High prevalence of multidrug-resistant tuberculosis, Swaziland, 2009-2010. Emerg Infect Dis 2012;18:29-37. [PMID: 22260950 DOI: 10.3201/eid1801.110850] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.8] [Reference Citation Analysis]
132 Naidoo K, Karim QA, Bhushan A, Naidoo K, Yende-Zuma N, McHunu PK, Frohlich J, Karim F, Upfold M, Kocheleff P, Abdool Karim SS. High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defic Syndr 2014;65:438-46. [PMID: 24256629 DOI: 10.1097/QAI.0000000000000060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
133 Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, Wood R. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011;15:571-81. [PMID: 21756508 DOI: 10.5588/ijtld.10.0483] [Cited by in Crossref: 72] [Cited by in F6Publishing: 72] [Article Influence: 7.2] [Reference Citation Analysis]
134 Abossie A, Yohanes T. Assessment of isoniazid preventive therapy in the reduction of tuberculosis among ART patients in Arba Minch Hospital, Ethiopia. Ther Clin Risk Manag 2017;13:361-6. [PMID: 28392698 DOI: 10.2147/TCRM.S127765] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
135 Castelli F, Pietra V, Diallo I, Schumacher RF, Simpore J. Antiretroviral (ARV) Therapy in Resource Poor Countries: What do we Need in Real Life? Open AIDS J 2010;4:28-32. [PMID: 20148089 DOI: 10.2174/1874613601004020028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
136 Ayele HT, Mourik MS, Debray TP, Bonten MJ. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One 2015;10:e0142290. [PMID: 26551023 DOI: 10.1371/journal.pone.0142290] [Cited by in Crossref: 50] [Cited by in F6Publishing: 39] [Article Influence: 8.3] [Reference Citation Analysis]
137 Krsulovic FA, Lima M. Tuberculosis Epidemiology at the Country Scale: Self-Limiting Process and the HIV Effects. PLoS One 2016;11:e0153710. [PMID: 27093296 DOI: 10.1371/journal.pone.0153710] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
138 Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human syndemic. Clin Microbiol Rev. 2011;24:351-376. [PMID: 21482729 DOI: 10.1128/cmr.00042-10] [Cited by in Crossref: 339] [Cited by in F6Publishing: 210] [Article Influence: 33.9] [Reference Citation Analysis]
139 Perumal R, Padayatchi N, Stiefvater E. The whole is greater than the sum of the parts: recognising missed opportunities for an optimal response to the rapidly maturing TB-HIV co-epidemic in South Africa. BMC Public Health 2009;9:243. [PMID: 19607697 DOI: 10.1186/1471-2458-9-243] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
140 Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-25. [PMID: 19461502 DOI: 10.1097/QAD.0b013e32832d3b6d] [Cited by in Crossref: 208] [Cited by in F6Publishing: 138] [Article Influence: 17.3] [Reference Citation Analysis]
141 Fenner L, Ballif M, Graber C, Nhandu V, Dusingize JC, Cortes CP, Carriquiry G, Anastos K, Garone D, Jong E, Gnokoro JC, Sued O, Ajayi S, Diero L, Wools-Kaloustian K, Kiertiburanakul S, Castelnuovo B, Lewden C, Durier N, Sterling TR, Egger M; International epidemiological Databases to Evaluate AIDS (IeDEA). Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One 2013;8:e77697. [PMID: 24147059 DOI: 10.1371/journal.pone.0077697] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
142 Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24 Suppl 5:S5-13. [PMID: 21079429 DOI: 10.1097/01.aids.0000391010.02774.6f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
143 Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study. AIDS. 2010;24 Suppl 5:S49-S56. [PMID: 21079428 DOI: 10.1097/01.aids.0000391022.95412.a6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
144 Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis. AIDS 2011;25:211-20. [PMID: 21124202 DOI: 10.1097/QAD.0b013e328340fdf8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
145 Piggott DA, Karakousis PC. Timing of antiretroviral therapy for HIV in the setting of TB treatment. Clin Dev Immunol 2011;2011:103917. [PMID: 21234380 DOI: 10.1155/2011/103917] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
146 Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008;8:89. [PMID: 18601727 DOI: 10.1186/1471-2334-8-89] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
147 Majigo M, Somi G, Joachim A, Manyahi J, Nondi J, Sambu V, Rwebembera A, Makyao N, Ramadhani A, Maokola W, Todd J, Matee MI. Prevalence and incidence rate of tuberculosis among HIV-infected patients enrolled in HIV care, treatment, and support program in mainland Tanzania. Trop Med Health 2020;48:76. [PMID: 33579394 DOI: 10.1186/s41182-020-00264-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
148 Lawn SD, Wood R, Wilkinson RJ. Changing concepts of "latent tuberculosis infection" in patients living with HIV infection. Clin Dev Immunol 2011;2011:980594. [PMID: 20936108 DOI: 10.1155/2011/980594] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
149 Jerene D, Naess A, Lindtjørn B. Antiretroviral therapy at a district hospital in Ethiopia prevents death and tuberculosis in a cohort of HIV patients. AIDS Res Ther 2006;3:10. [PMID: 16600050 DOI: 10.1186/1742-6405-3-10] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 2.5] [Reference Citation Analysis]
150 Salazar-Austin N, Dowdy DW, Chaisson RE, Golub JE. Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration. Am J Epidemiol 2019;188:2078-85. [PMID: 31364692 DOI: 10.1093/aje/kwz172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
151 Dieye TN, Ndiaye BP, Dieng AB, Fall M, Brittain N, Vermaak S, Camara M, Diop-Ndiaye H, Ngom-Gueye NF, Diaw PA, Toure-Kane C, Sow PS, Mboup S, McShane H. Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects. PLoS One 2013;8:e67177. [PMID: 23840618 DOI: 10.1371/journal.pone.0067177] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
152 Nachega JB, Morroni C, Chaisson RE, Goliath R, Efron A, Ram M, Maartens G. Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. Patient Prefer Adherence 2012;6:887-91. [PMID: 23271897 DOI: 10.2147/PPA.S38897] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
153 Chamie G, Wandera B, Marquez C, Kato-Maeda M, Kamya MR, Havlir DV, Charlebois ED. Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health 2015;20:537-45. [PMID: 25583212 DOI: 10.1111/tmi.12459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
154 Siev M, Wilson D, Kainth S, Kasprowicz VO, Feintuch CM, Jenny-Avital ER, Achkar JM. Antibodies against Mycobacterial proteins as biomarkers for HIV-associated smear-negative tuberculosis. Clin Vaccine Immunol 2014;21:791-8. [PMID: 24671553 DOI: 10.1128/CVI.00805-13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
155 Mathema B, Kurepina NE, Bifani PJ, Kreiswirth BN. Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 2006;19:658-85. [PMID: 17041139 DOI: 10.1128/CMR.00061-05] [Cited by in Crossref: 236] [Cited by in F6Publishing: 117] [Article Influence: 15.7] [Reference Citation Analysis]
156 Iroezindu MO, Ofondu EO, Mbata GC, van Wyk B, Hausler HP, Dh A, Lynen L, Hopewell PC. Factors Associated with Prevalent Tuberculosis Among Patients Receiving Highly Active Antiretroviral Therapy in a Nigerian Tertiary Hospital. Ann Med Health Sci Res 2016;6:120-8. [PMID: 27213096 DOI: 10.4103/2141-9248.181837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
157 Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23:631-636. [PMID: 19525621 DOI: 10.1097/qad.0b013e328327964f] [Cited by in Crossref: 152] [Cited by in F6Publishing: 90] [Article Influence: 13.8] [Reference Citation Analysis]